EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, CMOPF: Cosmo Pharma NV Ord

27 Oct 2026
LAST:

64.43

CHANGE:
 1.11		OPEN:
65.90		HIGH:
65.90		ASK:
0.00		VOLUME:
1.0K
CHG(%):
1.76		PREV:
63.32		LOW:
64.43		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Oct 2665.9065.9064.4364.431.0K
26 Oct 2664.3364.3363.3263.32100
23 Oct 2664.0064.0064.0064.00100
21 Oct 2664.3364.3364.3364.33100
20 Oct 2662.7562.7560.9062.75100
19 Oct 2664.6164.6164.0064.00100
16 Oct 2661.9265.4761.9262.95100
15 Oct 2662.5063.7662.5063.761.0K
14 Oct 2659.9260.2059.9259.92100
13 Oct 2660.0060.6459.0259.02400

PROFILE

Name:Cosmo Pharma NV Ord
About:Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Sector:Healthcare
Address:Riverside II, Dublin, Ireland, 2
Website:https://www.cosmopharma.com
CIK:0001915527
FIGI:BBG00FBD5N18

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:19.82 
Forward P/E:12.35 
Price to Sales:7.41 
Price to Book:2.45 
DivYield:0.03 
Div/Share:2.05 
Revenue:182.27M 
EBITDA:80.45M 
Shares:15.94M 
Market Cap:1.027B 

TECHNICAL INDICATORS

MA5:63.761.0%
MA10:62.852.5%
MA20:63.391.6%
MA50:67.775.2%
MA100:76.3018.4%
MA200:101.3057.2%
STO9:75.44
STO14:78.63
RSI14:51.25
MTM14:1.97
ROC14:0.03 
ATR:1.80 
Week High:65.902.3%
Week Low:60.905.8%
Month High:68.005.5%
Month Low:59.0257.2%
Volatility:8.44